StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 12.8 %
Shares of Evoke Pharma stock opened at $0.48 on Thursday. The stock has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.93. Evoke Pharma has a 12-month low of $0.42 and a 12-month high of $2.42.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 517.99% and a negative net margin of 150.43%. The firm had revenue of $1.68 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- What Does a Stock Split Mean?
- Comprehensive PepsiCo Stock Analysis
- There Are Different Types of Stock To Invest In
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Use the MarketBeat Dividend Calculator
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
